Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted FCF Margin of 26.07% for Q1 2026, up 286.91% on a QoQ basis from 6.74% in Q4 2025, and up 491.0% year-over-year from 4.41% in Q1 2025.
Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's FCF Margin history runs 18 years deep, the most recent figure standing at 26.07% for Q1 2026.
- Quarterly FCF Margin rose 491.0% year-over-year to 26.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.66% (up 250.0% YoY) and the FY2025 annual result came in at 22.51%, up 543.0% from the prior year.
- FCF Margin was 26.07% for Q1 2026 at Biomarin Pharmaceutical, up from 6.74% in the prior quarter.
- Across five years, FCF Margin topped out at 41.21% in Q3 2025 and bottomed at 23.5% in Q4 2022.
- A 5-year average of 12.77% and a median of 14.93% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin sank 3240 bps — and 2023, when it surged 3342 bps.
- Biomarin Pharmaceutical's FCF Margin stood at 23.5% in 2022, then surged by 142 bps to 9.92% in 2023, then jumped by 124 bps to 22.23% in 2024, then slumped by 70 bps to 6.74% in 2025, then jumped by 287 bps to 26.07% in 2026.
- Business Quant data shows BMRN's FCF Margin at 26.07% in Q1 2026, 6.74% in Q4 2025, and 41.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 26.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.07% |
| Dec 31, 2025 | 6.74% |
| Sep 30, 2025 | 41.21% |
| Jun 30, 2025 | 22.84% |
| Mar 31, 2025 | 21.15% |
| Dec 31, 2024 | 22.23% |
| Sep 30, 2024 | 27.22% |
| Jun 30, 2024 | 13.68% |
| Mar 31, 2024 | 3.22% |
| Dec 31, 2023 | 9.92% |
| Sep 30, 2023 | 12.64% |
| Jun 30, 2023 | 14.93% |
| Mar 31, 2023 | -16.50% |
| Dec 31, 2022 | -23.50% |
| Sep 30, 2022 | 31.92% |
| Jun 30, 2022 | 17.65% |
| Mar 31, 2022 | -14.30% |
| Dec 31, 2021 | 1.11% |
| Sep 30, 2021 | 23.57% |
| Jun 30, 2021 | 21.65% |